Kraig Biocraft FY26 Q2 net loss widens 25.26% to $909,535; revenue remains nil
KBLB•Management keeps production and uplist plans
Management kept its plan to expand commercial-scale recombinant spider silk production and pursue an uplist to a national exchange.
Quarterly loss widens as revenue remains nil
- Kraig Biocraft posted a Q2 net loss of USD 909,535, widening 25.26% from the year-ago quarter.
- Operating loss widened 10.3% to USD 703,433; revenue was unchanged at no revenue.
- General and administrative expense rose 8.82% to USD 374,381; professional fees climbed 60.14% to USD 69,862.
- Interest expense increased 6.63% to USD 151,399; interest income rose to USD 19,312 from USD 1,140.
